Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Targets |
CXCR4
|
---|---|
ln Vitro |
The robust (Ca)i response produced by NUCC-390 dihydrochloride (10 μM) can be inhibited by AMD3100, a powerful and selective CXCR4 antagonist that is well-known[1]. NuCC-390 dihydrochloride (10 μM; 30 min pre-treatment) increases pERK and can stimulate signaling downstream of CXCR4 receptors[1]. In HEK cells, CXCR4 receptor internalization may be induced by NUCC-390 dihydrochloride (10 μM; 2 hours), and untreated cells show some diffuse CXCR4-YFP expression in the cytoplasm and obvious expression in the cell membrane[1]. Via CXCR4, NUCC-390 dihydrochloride (0–1.25 μM; 24 hours) increases axonal development in cerebellar granule neurons (CGNs) in culture[2].
|
ln Vivo |
Following acute nerve terminal injury by α-LTx in CD-1 mice, NUCC-390 dihydrochloride (hind limb injection; 3.2 mg/kg; twice daily; 3 days) aids in the functional and morphological regeneration of the neuromuscular junction (NMJ)[2].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: C8161 cells Tested Concentrations: 10 μM Incubation Duration:Pre-treated 30 mins Experimental Results: Increased the level of pERK. Cell Proliferation Assay[2] Cell Types: Cerebellar granule neurons (CGNs) Tested Concentrations: 0 μM; 0.0625 μM; 0.25 μM; 1.25 μM Incubation Duration: 24 hrs (hours) Experimental Results: Stimulated axonal growth via CXCR4. |
Animal Protocol |
Animal/Disease Models: Six to eightweeks old CD1 mice[2]
Doses: 3.2 mg/kg Route of Administration: Hind limb injection; twice (two times) daily; 3 days Experimental Results: Promoted functional and anatomical recovery of the NMJ. |
References |
[1]. Mishra RK, et al. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists.Sci Rep. 2016 Jul 26;6:30155.
|
Molecular Formula |
C23H35CL2N5O
|
---|---|
Molecular Weight |
468.46
|
CAS # |
2749281-71-6
|
Related CAS # |
NUCC-390;1060524-97-1
|
SMILES |
C(N1CCCCC1)(C1=NN(CCC)C2CCC(NCCC3=CC=NC=C3)CC1=2)=O.Cl
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 100 mg/mL (213.47 mM)
H2O: 25 mg/mL (53.37 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 20 mg/mL (42.69 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1347 mL | 10.6733 mL | 21.3465 mL | |
5 mM | 0.4269 mL | 2.1347 mL | 4.2693 mL | |
10 mM | 0.2135 mL | 1.0673 mL | 2.1347 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.